Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Rhea-AI Summary
Lantheus Holdings (NASDAQ: LNTH), a leading radiopharmaceutical company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. CEO Brian Markison will present on Wednesday, September 4, at 7:45 a.m. ET.
Investors and interested parties can access a live webcast of the presentation through the Investors section of Lantheus' website at www.lantheus.com. The company will make a replay of the webcast available on its website for at least 30 days following the live presentation.
This conference participation underscores Lantheus' commitment to engaging with the investment community and sharing insights into its business focused on enabling clinicians to Find, Fight and Follow disease for improved patient outcomes.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, LNTH gained 0.51%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BEDFORD, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 7:45 a.m. ET on Wednesday, September 4.
To access a live webcast of the presentation, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcast will be available on the Company’s website for at least 30 days following the live presentation.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.
Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Senior Director, External Communications
646-975-2533
media@lantheus.com